A systematic review and meta-analysis of glucocorticoid-induced osteoporosis in children

ObjectiveTo summarize the published effects of systemic glucocorticoid therapy on bone mineral density (BMD) and fractures in children.MethodsWe performed a systematic review and meta-analysis of existing literature, using Medline, CINAHL, and Cochrane databases to identify studies of BMD or fractures in children ≤18 years taking systemic glucocorticoid therapy. We excluded studies of inhaled glucocorticoids, chemotherapy, and organ transplantation. Two authors reviewed abstracts for inclusion, read full-text articles to extract data, and rated each study using the Downs–Black scale.ResultsA total of 16 studies met eligibility criteria, including 10 BMD (287 children) and six fracture (37,819 children) studies. Spine BMD was significantly lower (−0.18; 95% CI = −0.25; −0.10 g/cm2) in children taking glucocorticoid therapy, compared to age- and gender-matched healthy controls. Spine BMD was also lower (−0.14; 95% CI = −0.27; 0.00 g/cm2) in children taking glucocorticoids, compared to children with the same disease not taking glucocorticoids. Incident clinical fracture rates varied from 2% to 33%. Morphometric vertebral fracture incidence ranged from 6% to 10%, and prevalence was 29–45%.ConclusionPublished data suggest that children treated with glucocorticoid therapy have lower spine BMD compared to healthy children. Whether children receiving glucocorticoid therapy have lower spine BMD compared to children with milder disease not requiring such therapy is not certain. Clinical and morphometric vertebral fractures are common, although only one study assessed fracture rates in healthy controls. Additional well-designed, prospective studies are needed to evaluate the skeletal effects of glucocorticoid therapy in children.